Who We Are
Battling Addiction Through Prevention
Bexson Biomedical was formed at the crossroads of necessity and experience. With opioid addiction being the deadliest drug crisis in American history, and nearly few meaningful pain management innovations in modern-day medicine, the prognosis for stopping the rise in addictions and overdoses has been bleak.
That’s why the meeting between co-founders Dr. Jeffrey Becker and Gregg Peterson, who partnered in 2017, proved pivotal. Their shared concern for the raging opioid crisis, along with their depth and breadth of combined professional experience sparked an innovative flame.
Bexson Biomedical was born out of the desperate need for potent, non-addictive pain management options
Armed with decades of experience in pharmaceuticals, medical device R&D, and NMDA-receptor pharmacology, the concept of a subcutaneous delivery system and formulation to repurpose ketamine and psychedelics for multiple large indications is in development.
To date Bexson has …
What We Do
Pioneering Medicine to Prevent Suffering
Bexson’s experienced team has a strong background in health innovation, clinical development and IP creation.
Bexson is developing modular subcutaneous delivery
platforms for controlled delivery of high value controlled
substances and other critical medications
in need of pharmacokinetic innovation.
Our Sub-Q delivery systems and formulation
technology is modular by design.
Our flagship projects are repurposing Ketamine, Flumazenil and Natural Psychedelics for multiple large-market indications in pain management, addiction and mental health.
Evolving Medicine Enhancing Lives
While our subcutaneous ketamine delivery system and formulation is priority focus, our modular technology is poised for repurposing toward additional therapies that aim to reduce the suffering associated with numerous large market pain and mental health indications.
Bexson Biomedical is developing a unique ketamine delivery system for pain disorders and mental health conditions. Our flagship project will deliver a proprietary subcutaneous formulation of ketamine via a minimally invasive, wearable, subcutaneous infusion pump to enable highly accurate delivery and dosing control.
